ArticleInternational journal of women's dermatology2026
Bone health in women with hidradenitis suppurativa: addressing osteoporosis risks and management options.
Article in International journal of women's dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder characterized by painful nodules and abscesses in intertriginous areas, predominantly affecting women. Persistent systemic inflammation and hormonal changes may contribute to reduced bone health and an increased risk of osteoporosis in this population. Objective: To highlight osteoporosis as an underrecognized comorbidity in women with HS and discuss contributing inflammatory, hormonal, and lifestyle-related risk factors that may predispose patients to bone compromise. Methods: A narrative review of the literature was conducted examining the relationship between HS, chronic inflammation, menopause-related estrogen decline, and osteoporosis risk. Additional contributory factors commonly associated with HS, including tobacco use, vitamin D deficiency, obesity, physical inactivity, and repeated corticosteroid exposure, were evaluated. Results: Systemic inflammation, hormonal decline, corticosteroid exposure, vitamin D deficiency, and reduced activity may contribute to increased osteoporosis risk in women with HS. Limitations: Current evidence evaluating osteoporosis risk specifically in patients with HS remains limited, and additional prospective studies are needed to better characterize prevalence, mechanisms, and screening recommendations. Conclusion: Bone health should be considered in women with HS, particularly those with severe or longstanding disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.